Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINARA: AZD5462 in Stable Chronic Heart Failure
jRCT2051240066Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of AZD5462 in chronic heart failure (CHF) (4 cohorts), sponsored by AstraZeneca. Primary endpoint: Change from baseline in ejection fraction (Cohorts A and B). Started Jul 2024; status: completed.
02
Drugs
AZD5462
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCT2051240066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240066.